 "Cadila Healthcare")
Ahmedabad-based drug major Cadila Healthcare is testing if a two-dose regimen of its DNA-plasmid vaccine ZyCoV-D works instead of a three-dose one, showing similar levels of efficacy.
The company is conducting phase 3 efficacy trials on a three-dose regimen of its DNA plasmid technology-based Covid-19 vaccine, which is in its last leg.
It expects to generate adequate data from clinical trials by May and subsequently seek approval from the country’s drugs regulator.
Sharvil Patel, managing director of Cadila Healthcare, told Business Standard the firm was working on trials to check if a two-dose regimen also worked.
The company is conducting phase 3 efficacy trials on a three-dose regimen of its DNA plasmid technology-based Covid-19 vaccine, which is in its last leg.
It expects to generate adequate data from clinical trials by May and subsequently seek approval from the country’s drugs regulator.
Sharvil Patel, managing director of Cadila Healthcare, told Business Standard the firm was working on trials to check if a two-dose regimen also worked.
